financetom
Business
financetom
/
Business
/
Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Affimed Reports Efficacy, Safety Data From Leukemia Treatment Study
Dec 9, 2024 11:29 AM

02:02 PM EST, 12/09/2024 (MT Newswires) -- Affimed ( AFMD ) said Monday that AFM28 showed "promising" efficacy and safety results evaluating the drug candidate in patients with relapsed/refractory acute myeloid leukemia in an ongoing phase 1 study.

The drug candidate reached a 40% composite complete remission rate at the highest dose level of 300 milligrams in heavily pretreated patients, the company said.

The company said AFM28 showed a "favorable" safety profile, with no signs of neurotoxicity or immune-related side effects seen.

Affimed ( AFMD ) said the assessment of higher dose levels is being planned, based on the safety profile and the likely dose-effect relationship.

Price: 2.27, Change: -0.06, Percent Change: -2.58

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved